2 Top Biotech Stocks to Buy Right Now
Income investing can be a great strategy for people looking to match their recurring bills with recurring dividend Income. The trick is diversifying across top businesses in numerous industries to build an unstoppable stream of passive Income.
Many leading pharmaceutical companies are known for reliably paying dividends to shareholders. Swiss drugmaker (NYSE: NVS) and French drugmaker Sanofi (NASDAQ: SNY) each look like smart picks for income investors. Here's why these two top biotech stocks are potential buys right now.
Including its Sandoz generics and biosimilars business which is expected to complete a spinoff in the second half of this year, Novartis' products treat almost 800 million people around the world. With such an extensive reach, it's not shocking that the company has 14 medicines that are on pace to top $1 billion in revenue. Leading the way, heart failure treatment Entresto is set to surpass $6 billion in 2023 revenue. As an idea of just how well-rounded a portfolio Novartis boasts, Entresto made up just 11% of its $26.6 billion in total revenue in the first half of 2023.
Source Fool.com
Novartis AG ADR Aktie
Einige Buy-Einschätzungen dominieren bei Novartis AG ADR gegenüber Sell-Einschätzungen.
Ein Kursziel von 150 € für Novartis AG ADR impliziert ein leicht positives Wachstum gegenüber dem aktuellen Kurs von 131.0 €.
